71 -10 (72) 2024 - Boboeva R.R., Yanchenko S.V. - CLINICAL ASSESSMENT OF CHANGES IN THE POSTERIOR SEGMENT OF THE EYE AGAINST THE BACKGROUND OF METABOLIC SYNDROME

CLINICAL ASSESSMENT OF CHANGES IN THE POSTERIOR SEGMENT OF THE EYE AGAINST THE BACKGROUND OF METABOLIC SYNDROME

Boboeva R.R. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Yanchenko S.V. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Safarov J.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Metabolic syndrome (MS) is a general concept that unites a group of diseases or pathological conditions with a common cause. Metabolic syndrome is a very common clinical condition, affecting on average one in five adults in developed countries. Against the background of metabolic syndrome, it is necessary to have a broader and more complete understanding of the mechanism of development of eye diseases, etiological factors, and the causes of the development of the disease. This means that early detection of risk factors, prompt treatment and intervention can reduce the risk of developing some eye diseases.

Key words: metabolic syndrome, blindness, retinopathy

First page

411

Last page

414

For citation:Boboeva R.R., Yanchenko S.V., Safarov J.O. - CLINICAL ASSESSMENT OF CHANGES IN THE POSTERIOR SEGMENT OF THE EYE AGAINST THE BACKGROUND OF METABOLIC SYNDROME//New Day in Medicine 10(72)2024 411-414 https://newdayworldmedicine.com/en/new_day_medicine/10-72-2024

List of References

1. Alessi M. C., Juhan–Vague I. PAI–1 and the metabolic syndrome: the links, causes and consequences. //Arterioscler Thromb Vasc Biol 2006;26(10):2200–7
2. Vong TY, Klеin R, Klеin BЕ, Tiеlsch JM, Hubbard L, Niеto FJ. Rеtinal mikrovaskulyar anomaliyalar va ularning gipеrtеnziya, yurak-qon tomir kasalliklari va o'lim bilan aloqasi. 2001;46:59-80.
3. Atlasz T.; Szabadfi K.; Kiss P.; Babai N.; Koszegi Z.; Tamas A.; Reglodi D.; Gabriel R. PACAP-mediated neuroprotection of neurochemically defined cell types in MSG-induced retinal degeneration 2008;36:97-104.
4. Raman R, Gupta A, Pal SS va boshqalar. Diabetol metab sindromi. 2010;2:67.
5. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. //Diabetes. 1998;47:1643-9.
6. Аметов А.С., Карпова Е.В. Ранняя комбинированная терапия при сахарном диабете 2 типа //Сахарный диабет. 2011;3:80-83.
7. Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б. и др. Инициatsiя и интенсификatsiя сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015 г.) //Сахарный диабет. 2015;1:5-23.
8. Мошетова Л.К., Воробьева И.В., Алексеев И.Б., Михалева Л.Г. Результаты лечения антиоксидантными и ангиопротекторными препаратами пatsiентов с диабетической ретинопатией и возрастной макулярной дегенерatsiей при сахарном диабете 2-го типа //Вестн. офтальмол. 2015;3:15-21.
9. Boboeva Ranо Rakhimovna. Improvement of Methods of Treatment of Retinal Angiopathies of Various Etiologies: //Journal of Natural and Medical Education Year 2024;3(2).
10. Mavlonov Anvar, Saidov Saidamir, Mirsultanov Jakhongir, Boboeva Rano Features of bone destruction in rabbits with experimental metabolic syndrome. //The Scientific Temper 2024;15(1):1941-1948 E-ISSN: 2231-6396, ISSN: 0976-8653
11. Бобоева Раъно Рахимовна. Совершенствование методов лечения ангиопатий сетчатки различной этиологии. //Journal of science in medicine and life. 2024; с. 61-65.

    file

    download